நிதி தகவல் இருந்து தொடர்கிறது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிதி தகவல் இருந்து தொடர்கிறது. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிதி தகவல் இருந்து தொடர்கிறது Today - Breaking & Trending Today

Abbott Reports Second-Quarter 2021 Results

Abbott Reports Second-Quarter 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Abbott Binax , Robertb Ford , Abbott Laboratories , Core Laboratory , Adult Nutrition , Medical Devices , Heart Failure , Structural Heart , Pediatric Nutrition , Molecular Diagnostics , Emerging Markets , Diabetes Care , Aristocrats Index , Investor Relations , Private Securities Litigation Reform Act , Caution Concerning Forward Looking , Annual Report , Consolidated Statement , Quarter Ended June , Operating Cost , Continuing Operations , Discontinued Operations , Common Share , Specified Items , Common Shares ,

Abbott Reports First-Quarter 2021 Results

Share this article
Share this article
ABBOTT PARK, Ill., April 20, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.
First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.
First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32, reflecting 103.1 percent growth versus the prior year.
1
Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74. Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year. ....

Abbott Binax , Prnewswire Abbott , Robertb Ford , Us Centers For Medicare Medicaid Services , Drug Administration , Core Laboratory Diagnostics , Abbott Laboratories , Core Laboratory , Medicaid Services , Virtual Clinic , Emergency Use Authorization , Self Test , Adult Nutrition , Pediatric Nutrition , Molecular Diagnostics , Emerging Markets , Medical Devices , Diabetes Care , Libre Sense , Freestyle Libre , Generally Accepted Accounting Principles , Aristocrats Index , Investor Relations , Private Securities Litigation Reform Act , Caution Concerning Forward Looking , Annual Report ,

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

Share this article
Share this article
ABBOTT PARK, Ill., Jan. 27, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021.
Fourth-quarter sales of $10.7 billion increased 28.7 percent on a reported basis and 28.4 percent on an organic basis, which excludes the impact of foreign exchange.
Fourth-quarter GAAP diluted EPS was $1.20 and adjusted diluted EPS, which excludes specified items, was $1.45, reflecting 52.6 percent growth versus the prior year.
1
Full-year 2020 GAAP diluted EPS from continuing operations was $2.49 and adjusted diluted EPS from continuing operations was $3.65, at the upper-end of guidance range issued in January 2020. ....

Markp Christiansen , Kristin Castorino , Hanqing Liu , Gregory Forlenza , Ronald Brazg , Mark Kipnes , Robertb Ford , Abbott Binax , Davidr Liljenquist , Erwins Budiman , Timothy Bailey , Alva Shridhara , World Health Organization , Abbott Laboratories , Cephea Valve Technologies Inc , Core Laboratory , Freestyle Libre , Libre Sense Glucose Sport Biosensor , Adult Nutrition , Pediatric Nutrition , Use Authorization , Emerging Markets , Product Lines , Medical Devices , Diabetes Care , Aristocrats Index ,